Journal
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
Volume 22, Issue 4, Pages 1171-1188Publisher
SPRINGER
DOI: 10.1007/s11154-021-09669-7
Keywords
Type 2 Diabetes; Obesity; Bariatric surgery; Glucagon-like-peptide 1; Blood vessel repair and regeneration; Cardiovascular disease
Categories
Funding
- Canadian Institutes of Health Research (CIHR) [378189]
- Amarin
- Amgen
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly
- EOCI Pharmacomm Ltd
- HLS Therapeutics
- Janssen
- Merck
- Novartis
- Novo Nordisk
- Pfizer
- PhaseBio
- Sanofi
- Sun Pharmaceuticals
- Toronto Knowledge Translation Working Group
Ask authors/readers for more resources
Type 2 diabetes and obesity lead to systemic oxidative stress and inflammation, depleting vascular regenerative cells and impairing blood vessel repair, known as 'regenerative cell exhaustion'. Research suggests that improving dysglycemia can reduce oxidative stress and promote recovery of circulating pro-vascular progenitor cells essential for vascular repair.
Type 2 diabetes (T2D) and obesity represent entangled pandemics that accelerate the development of cardiovascular disease (CVD). Given the immense burden of CVD in society, non-invasive prevention and treatment strategies to promote cardiovascular health are desperately needed. During T2D and obesity, chronic dysglycemia and abnormal adiposity result in systemic oxidative stress and inflammation that deplete the vascular regenerative cell reservoir in the bone marrow that impairs blood vessel repair and exacerbates the penetrance of CVD co-morbidities. This novel translational paradigm, termed 'regenerative cell exhaustion' (RCE), can be detected as the depletion and dysfunction of hematopoietic and endothelial progenitor cell lineages in the peripheral blood of individuals with established T2D and/or obesity. The reversal of vascular RCE has been observed after administration of the sodium-glucose cotransporter-2 inhibitor (SGLT2i), empagliflozin, or after bariatric surgery for severe obesity. In this review, we explore emerging evidence that links improved dysglycemia to a reduction in systemic oxidative stress and recovery of circulating pro-vascular progenitor cell content required for blood vessel repair. Given that bariatric surgery consistently increases systemic glucagon-like-peptide 1 (GLP-1) release, we also focus on evidence that the use of GLP-1 receptor agonists (GLP-1RA) during obesity may act to inhibit the progression of systemic dysglycemia and adiposity, and indirectly reduce inflammation and oxidative stress, thereby limiting the impact of RCE. Therefore, therapeutic intervention with currently-available GLP-1RA may provide a less-invasive modality to reverse RCE, bolster vascular repair mechanisms, and improve cardiometabolic risk in individuals living with T2D and obesity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available